Personalized mRNA vaccine keeps most breast cancer patients in remission
An individualized mRNA vaccine has kept most women with triple negative breast cancer in long term remission, according to results published in Nature, offering new evidence that tailored immunotherapy may provide durable protection against one of the most aggressive forms of the disease.
The study, released on February 17, 2026, found that 11 of 14 patients treated with a personalized mRNA vaccine remained cancer free for up to six years after therapy. Ten participants were still without evidence of disease at the time of analysis. The early phase trial tested vaccines designed specifically for each patient, targeting mutated proteins unique to their tumors in order to stimulate a focused immune response.
Researchers reported that 86 percent of heavily pretreated patients developed strong neoantigen specific immune responses. Neoantigens are abnormal proteins produced by tumor specific mutations, making them distinct from healthy tissue and ideal targets for precision immunotherapy. By encoding these neoantigens into customized mRNA sequences, the vaccine trained the immune system to identify and attack cancer cells carrying those mutations.
The findings indicate that vaccine induced T cells expanded to measurable levels within circulating immune cells, representing a substantial anti tumor response. Importantly, the study showed that these T cells matured into two complementary forms: cytotoxic effector cells capable of directly destroying tumor cells, and stem like memory cells able to persist over time and regenerate the immune response.
This dual development is considered critical for sustained cancer control. Effector cells provide immediate tumor killing capacity, while memory cells maintain long term immune surveillance, reducing the likelihood of relapse. In this trial, T cell responses remained detectable for up to six years after vaccination, suggesting that the therapy can establish prolonged immune protection.
Three patients experienced a recurrence of their cancer, offering insights into how tumors may evade immune defenses. In one case, the recurrent tumor exhibited downregulation of major histocompatibility complex class I molecules, a recognized mechanism that allows cancer cells to escape detection by T cells. Such immune escape pathways remain a key challenge in oncology and highlight the need for combination approaches that reinforce immune recognition.
Triple negative breast cancer accounts for approximately 15 to 20 percent of all breast cancer cases. It is defined by the absence of estrogen receptors, progesterone receptors and HER2 expression, making it unresponsive to hormonal or HER2 targeted therapies. Patients with this subtype face a recurrence rate of roughly 40 percent within five years, underscoring the need for new preventive strategies following initial treatment.
The personalized mRNA vaccine approach aims to reduce relapse risk by establishing robust anti tumor immunity before residual cancer cells can reemerge. Unlike conventional therapies that broadly target rapidly dividing cells, this strategy uses genetic sequencing of each patient’s tumor to identify mutations and design a vaccine tailored to those specific alterations.
The research builds on earlier work involving individualized neoantigen vaccines in other cancers. BioNTech and Genentech are developing autogene cevumeran, a personalized mRNA therapy targeting tumor specific neoantigens, which has shown promising results across several solid tumors. Previous trials demonstrated that the platform can induce poly epitope immune responses involving both CD4 positive helper T cells and CD8 positive cytotoxic T cells in most treated patients.
While the current findings are based on a small cohort, investigators say the durability of the immune responses and the extended remission observed in most participants support further clinical development. Larger randomized trials will be required to confirm efficacy and determine whether personalized mRNA vaccination can become part of standard treatment for high risk breast cancer patients.
The results contribute to growing evidence that mRNA technology, initially deployed at scale during the COVID 19 pandemic, can be adapted for precision oncology. By harnessing the immune system to recognize each tumor’s unique mutation profile, researchers hope to shift cancer care toward long term immune control rather than repeated cycles of relapse and treatment.
-
14:14
-
14:00
-
13:45
-
13:30
-
13:05
-
12:47
-
12:30
-
12:24
-
12:15
-
12:12
-
11:58
-
11:41
-
11:25
-
11:17
-
11:14
-
11:11
-
11:00
-
10:47
-
10:30
-
10:30
-
10:15
-
10:00
-
09:42
-
09:38
-
09:25
-
09:18
-
09:09
-
08:45
-
08:30
-
08:15
-
00:45
-
00:30
-
00:15
-
23:55
-
23:45
-
23:35
-
23:30
-
23:15
-
23:00
-
22:45
-
22:32
-
22:15
-
22:05
-
21:54
-
21:45
-
21:30
-
21:15
-
21:00
-
20:45
-
20:32
-
20:15
-
20:00
-
19:47
-
19:31
-
19:15
-
19:00
-
18:45
-
18:32
-
18:15
-
18:00
-
17:45
-
17:30
-
17:24
-
17:15
-
16:56
-
16:55
-
16:48
-
16:40
-
16:35
-
16:25
-
16:16
-
16:10
-
16:05
-
15:59
-
15:47
-
15:34
-
15:30
-
15:15
-
15:00
-
14:46
-
14:45
-
14:45
-
14:32
